Scottish Medicines Consortium (SMC) accepts Camzyos®▼(mavacamten) for use on the NHS as an adjunct treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy

Press/Media: Research

Period4 Aug 2024

Media contributions

1

Media contributions

  • TitleScottish Medicines Consortium (SMC) accepts Camzyos®▼(mavacamten) for use on the NHS as an adjunct treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy
    Media name/outletFirstWord Pharma
    Media typeWeb
    Country/TerritoryUnited States
    Date4/08/24
    PersonsMarc Dweck